Nyxoah (NASDAQ:NYXH) vs. Alpha Tau Medical (NASDAQ:DRTS) Head to Head Contrast

Alpha Tau Medical (NASDAQ:DRTS) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alpha Tau Medical and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	0	0	3	0	3.00
Nyxoah	0	0	5	0	3.00

Alpha Tau Medical currently has a consensus price target of $8.00, suggesting a potential upside of 179.72%. Nyxoah has a consensus price target of $17.00, suggesting a potential upside of 108.85%. Given Alpha Tau Medical’s higher probable upside, analysts plainly believe Alpha Tau Medical is more favorable than Nyxoah.

Profitability

This table compares Alpha Tau Medical and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-38.62%	-29.89%
Nyxoah	-1,043.93%	-51.68%	-40.11%

Earnings and Valuation

This table compares Alpha Tau Medical and Nyxoah”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.43)	-6.65
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.87)	-4.35

Alpha Tau Medical has higher earnings, but lower revenue than Nyxoah. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

2.7% of Alpha Tau Medical shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Alpha Tau Medical has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.

Summary

Alpha Tau Medical beats Nyxoah on 8 of the 12 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.